News

According to the current Budget Request, FDA would like to perform approx. 20 percent more foreign GMP inspections. Read more.

More

The EMA Database EudraGMDP is a major achievement for GMP and GDP compliance information.  Since parts of the data are now publicly accessible, it makes it easier to get important information relevant for supplier qualification. In our GMP News we list the 2014 updates for GMP-Non-Compliance.

More

The so called Food and Drug Administration Safety and Innovation Act (FDASIA) requires the FDA to publish reports on the inspection of registered establishments every year starting with the fiscal year 2013. The first Annual Report is available now. Read more about the Annual Inspections Report.

More

The US FDA and the European Union have increased their GMP Inspection Systems significantly. As a result more inspections are being performed outside their own territory.  Now the FDA has issued an Import Alert for two Chinese manufacturers. Read more about the FDA Import Alert.

More

During her visit in India, FDA Commissioner Margaret A. Hamburg stated that inspections in India will be increased. Read more.

More

GMP deviations and even data falsification have been identified in a number of companies in India. How is it possible that interpretation of FDA and EU authorities on one side and the Indian authority on the other side come to a completely different picture? Read more in our GMP News

More

Many pharmaceutical companies would like to achieve a so-called "FDA Readiness". But what should be understood under this term? Read more here.

More

As already reported, the EMA has started listing so-called GMP Non Compliance Statements in the EudraGMDP database in addition to Certificates of GMP Compliance. Now, detailed information has been made publicly available. Read more in the News.

More

With their new budget, FDA will be able to increase drug plant inspections worldwide and especially in China. Read more.

More

For quite some time, the US FDA has elaborated concrete plans to increase the number of inspections in China. These plans were developed as a consequence of the Heparin crisis. Based on a new agreement with China, the US FDA will now increase the number of inspections significantly. Read more.

More
x